Pemetrexed Plus Cisplatin or Pemetrexed Plus Carboplatin for Chemonaïve Patients with Malignant Pleural Mesothelioma: Results of the International Expanded Access Program
Armando Santoro(Fondazione Humanitas per la Ricerca), Mary O’Brien(Royal Marsden Hospital), Rolf A. Stahel(University Hospital of Zurich), Kristiaan Nackaerts(KU Leuven), Paul Baas(Dutch Cancer Society), Meinolf Karthaus(München Klinik Neuperlach), Wilfried Eberhardt, Luis Paz‐Ares(Hospital Universitario 12 De Octubre), Stein Sundstrøm(St Olav's University Hospital), Yushan Liu(iRepertoire (United States)), Veronique Ripoche(Eli Lilly (United States)), J. Blatter(Eli Lilly (United States)), Carla Visseren‐Grul(Eli Lilly (United States)), Christian Manegold(Heidelberg University)
Cited by 253
Abstract
Related Papers
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Patrick Therasse, Susan G. Arbuck, Elizabeth A. Eisenhauer et al.|JNCI Journal of the National Cancer Institute|2000|15.7k
Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma
Nicholas J. Vogelzang, James J. Rusthoven, James T. Symanowski et al.|Journal of Clinical Oncology|2003|3.1k